G J Veal
Overview
Explore the profile of G J Veal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duong J, Veal G, Nath C, Shaw P, Errington J, Ladenstein R, et al.
Br J Clin Pharmacol
. 2018 Sep;
85(1):136-146.
PMID: 30261554
Aims: Carboplatin dosage is calculated by using the estimated glomerular filtration rate (GFR) to achieve a target plasma area under the plasma concentration-time curve (AUC). The aims of the present...
2.
Vormoor B, Veal G, Griffin M, Boddy A, Irving J, Minto L, et al.
Pediatr Blood Cancer
. 2016 Dec;
64(6).
PMID: 27905678
Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic...
3.
Veal G, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, et al.
Eur J Cancer
. 2012 Jun;
48(16):3063-72.
PMID: 22742881
Introduction: Busulfan is widely used in a neuroblastoma setting, with several studies reporting marked inter-patient variability in busulfan pharmacokinetics and pharmacodynamics. The current study reports on the pharmacokinetics of oral...
4.
Illingworth N, Boddy A, Daly A, Veal G
Br J Pharmacol
. 2010 Nov;
162(4):989-99.
PMID: 21054342
Background And Purpose: Fenretinide (4-HPR) is a retinoic acid analogue, currently used in clinical trials in oncology. Metabolism of 4-HPR is of particular interest due to production of the active...
5.
Chinnaswamy G, Cole M, Boddy A, Keir M, Price L, Parry A, et al.
Br J Cancer
. 2008 Sep;
99(6):894-9.
PMID: 18781149
Renal function-based carboplatin dosing is used routinely in paediatric oncology clinical practice. It is important that accurate assessments of renal function are carried out consistently across clinical centres, a view...
6.
Picton S, Keeble J, Holden V, Errington J, Boddy A, Veal G
Cancer Chemother Pharmacol
. 2008 Jul;
63(4):749-52.
PMID: 18607591
Introduction: Carboplatin dosing based on renal function and therapeutic monitoring have been previously shown to be beneficial in the treatment of children with cancer. However, the applicability of such approaches...
7.
Armstrong J, Taylor G, Thomas H, Boddy A, Redfern C, Veal G
Br J Cancer
. 2007 May;
96(11):1675-83.
PMID: 17486130
Isomerisation to all-trans-retinoic acid (ATRA) is widely accepted as the key mechanism underlying the favourable clinical properties of 13-cis-retinoic acid (13cisRA). As intracellular metabolism of ATRA by CYP26 may result...
8.
Veal G, Errington J, Tilby M, Pearson A, Foot A, McDowell H, et al.
Br J Cancer
. 2007 Feb;
96(5):725-31.
PMID: 17299395
A pharmacokinetic-pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic monitoring following high-dose carboplatin treatment in children. High-dose carboplatin was administered over 3 or 5...
9.
Veal G, Cole M, Errington J, Pearson A, Foot A, Whyman G, et al.
Br J Cancer
. 2007 Jan;
96(3):424-31.
PMID: 17224928
The administration of 13-cis-retinoic acid (13-cisRA), following myeloablative therapy improves 3-year event-free survival rates in children with high-risk neuroblastoma. This study aimed to determine the degree of inter-patient pharmacokinetic variation...
10.
Cole M, Price L, Parry A, Picton S, Waters F, Marshall S, et al.
Pediatr Blood Cancer
. 2006 May;
48(7):687-95.
PMID: 16676305
Background: The objective of this study was to determine the minimum volume of blood that should be discarded from a range of different types of central venous catheter (CVC), such...